Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. (A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes)
https://doi.org/10.14341/probl200753533-40
Abstract
This Russian translation and reprint of the original article published with authors permissions. Original article published in the Diabetes Care. 2006;29(8). Translation to Russian prepared by Yu. Sych. An abridged version of the article was prepared by A. Gorbovskaya.
These recommendations and the algorithm are based on data from clinical studies of various treatment options for type 2 diabetes and on the personal experience of consensus participants, taking into account the main goal of treatment - to achieve and maintain glucose levels as close as possible to glycemia in healthy people. The lack of evidence of high levels of glycemia obtained in comparative clinical trials with a direct comparison of different treatment options for diabetes remains the main obstacle to isolating one main class of drugs or combination of drugs that have advantages over others.
About the Authors
D. M. NathanDiabetes Center, Massachusetts General Hospital and Harvard Medical School
United States
J. В. Buse
University of North Carolina School of Medicine
United States
M. В. Davidson
Charles R. Drew University
Russian Federation
Clinical Trials Unit
R. J. Heine
VU University Medical Center
Netherlands
Diabetes Center
R. R. Holman
Oxford University
United Kingdom
Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism
R. Sherwin
Yale University School of Medicine
United States
Departament of Internal Medicine and Endocrinology
B. Zinman
University of Toronto
United States
Departments of Endocrinology and Metabolism, Mount Sinai Hospital
References
1. American Diabetes Association. Standards of medical care of diabetes. Diabetes Care 28 (Suppl. 1): S15-S35, 2005.
2. European Diabetes Policy Group: A desk-top guide to type 2 diabetes mellitus. Diabet Med. 16: 716-730, 1999.
3. The Royal College of General Practitioners Effective Clinical Practice Unit: Clinical guidelines for type 2 diabetes mellitus: management of blood glucose, 2002. Available from http://www.nice.org.uk/pdf/NICE_full_blood_glucose.pdf
4. Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N. Engl. J. Med. 329: 978-986, 1993.
5. Reichard P., Nilsson B.-Y., Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N. Engl. J. Med. 329: 304-309, 1993.
6. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837- 853, 1998.
7. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854-865, 1998.
8. Ohkubo Y., Kishikawa H., Araki E. et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with NIDDM: a randomized prospective 6-year study. Diabetes Res. Clin. Pract. 28: 103-117, 1995.
9. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes. N. Engl. J. Med. 348: 2294-2303, 2003.
10. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N. Engl. J. Med. 353: 2643-2653, 2005.
11. Advance Collaborative Group: ADVANCE: Action in Diabetes and Vascular Disease: patient recruitment and characteristics of the study population at baseline. Diabet. Med. 22: 882- 888, 2005.
12. American Diabetes Association: Standards of medical care in diabetes-2006. Diabetes Care 29 (Suppl. I): S4-S42, 2006.
13. National Institutes of Health: Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: The Evidence Report. Bethesda, National Institutes of Health, 1999.
14. Groop L. Sulfonylureas in NIDDM. Diabetes Care 15: 737- 747, 1992.
15. Bailey C. J., Turner R. С Metformin. N. Engl. J. Med. 334: 574-583, 1996.
16. Malaisse W. J. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat. Endocrinol. 2: 401-414, 2003.
17. Van de Laar F. A., Lucassen P. L, Akkermans R. P. et al. Alpha-glucosidase inhibitors for type 2 diabetes mellitus. Cochrane Database Syst. Rev. CD003639, 2005.
18. Genuth S. Insulin use in NIDDM. Diabetes Care 13: 1240- 1264, 1990.
19. Ykl-Jarvinen H. Drug therapy: thiazolidinediones. N. Engl. J. Med. 351:1106, 2004.
20. Drucker D. J. Biologic actions and therapeutic potential of the proglucagon-derived peptides. Nature Endocrinol. Metab. 1: 22-31, 2005.
21. Schmitr O., Brock В., Rungby J. Amylin agonists: a novel approach in the treatment of diabetes. Diabetes 53 (Suppl. 3): S233-S238, 2004.
22. Colagiuri S., Cull С A., Holman R. R., UKPDS Group. Are lower fasting plasma glucose levels at diagnosis of type 2 daia-betes associated with improved outcomes? Diabetes Care 25: 1410-1417, 2002.
23. Harris M. I. Epidemiologic correlates of NIDDM in Hispanics, whites and blacks in the U. S. population. Diabetes Care 14 (Suppl. 3): 639-648, 1991.
24. Rewers M., Hamman F. R. Risk factors for non-insulin dependent diabetes. In: Diabetes in America, 2-nd ed. Harris M., Ed. Bethesda, National Institutes of Health, 1995, P. 179- 220.
25. Pories W. J., Swanson M. S., MacDonald K. G. et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann. Surg. 222: 339-350, 1995.
26. Sjostrom L., Llndroos A. K., Peltonen M. et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351: 2683-2693,2004.
27. Pontiroli A. E., Folli F., Paganelll M. et al. Laparoscopic gastric banding prevents type 2 diabetes and arterial hypertension and induces their remission in morbid obesity. Diabetes Care 28: 2703-2709, 2005.
28. Diabetes Prevention Program Research Group: Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the Diabetes Prevention Program. Diabetes Care 28: 888-894, 2005.
29. DeFronzo R., Goodman A. Multicenter Metformin Study Group: Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 333: 541, 1995.
30. Salpeter S., Greyber E., Pasternak G., Salpeter E Risk of fatal and nonfatal lactic acidosis with metfromin use in type 2 diabetes mellitus. Cochrane Database Syst. Rev. CD002967, 2006.
31. Diabetes Prevention Program Research Group. Reduction in incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346: 393-403, 2002.
32. Rosenstock J., Hassman D. R., Madder R. D. et al. Repaghnide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27: 1265-1270, 2004.
33. Gerich J., Raskin P., Jean-Louis L. et al. PRESERVE-p: two-year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28: 2093-2100, 2005.
34. Chlasson J. L., Josse R. G., Gomis R. et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM Trial. J. A. M. A. 290: 486-494, 2003.
35. Nathan D. M., Roussell A., Godine J. E. Glyburide or insulin for metabolic control in non-insulin-dependent diabetes mellitus: a randomized double-blind study. Ann. Intern. Med. 108: 334-340, 1988.
36. Abraira C, Johnson N., Cohvell J., VA CSDM Group. VA Cooperative study on glycemic control and complications in type II diabetes. Diabetes Care 18:1113-1123, 1995.
37. Zammitt N. N, Frier В. М. Hypoglycemia in type 2 diabetes. Diabetes Care 28: 2948-2961, 2005.
38. Miller С. D., Phillips L S., Ziemer D. С. et al. Hypoglycemia in patients with type 2 diabetes mellitus. Arch. Intern. Med. 161:1653-659, 2005.
39. Kendall D. M., Riddle M. C, Rosenstock J. et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28: 1083-1091, 2005.
40. DeFronzo R., Ratner R. E., Han J. et al. Effects of exenatide on glycemic control and weight oover 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28: 1092- 1100. 2005.
41. Buse J. В., Henry R. R., Han J. et al. Effects of exenatide on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27: 2628-2635, 2004.
42. Heine R. J., Van Goal L. F., Johns D. et al. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann. Intern. Med. 143: 559-569, 2005.
43. Hollander P. A., Levy P., Fineman M. S. et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes. Diabetes Care 26: 784-790, 2003.
44. Schwartz S., Sievers R., Strange P. et al. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs. Diabetes Care 26: 2238-2243, 2003.
45. Ykl-Jarvinen H., Ryysy L., Nikkila K. et al. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. Ann. Intern. Med. 130: 389-396, 1999.
46. Strowig S., Aviles-Santa M. L., Raskin P. Improved glycemic control without weight gain using triple therapy in type 2 diabetes. Diabetes Care 27: 1577-1583, 2004.
47. Fonseca V., Rosenstock J., Patwardhan R., Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus. J. A. M. A. 283: 1695-1702, 2000.
48. Bailey C. J., Bagdonas A., Rubes J. et al. Rosightazone/met-formin fixed dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24 week, multicent-er, randomized, double blind, parallel group study. Clin. Ther. 27: 1548-1561, 2005.
Review
For citations:
Nathan D.M., Buse J.В., Davidson M.В., Heine R.J., Holman R.R., Sherwin R., Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. (A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes). Problems of Endocrinology. 2007;53(5):33-40. (In Russ.) https://doi.org/10.14341/probl200753533-40
Views:
9620
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
.jpg){kind=logo}
